HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ORIC Pharmaceuticals (NASDAQ:ORIC) and maintained a $21 price target.
August 14, 2024 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on ORIC Pharmaceuticals and maintained a $21 price target.
The reiteration of a Buy rating and the maintenance of a $21 price target by a reputable analyst can boost investor confidence in ORIC Pharmaceuticals, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100